Kasten, Inc. Announces Agreement for Sublicensing of Novel Formulation of Bactracin for Drug Resistant Bacteria

November 14, 2016
market-shares-image
Kasten, Inc. Announces Shareholder Update on Company Direction
November 10, 2016
Kasten, Inc. Announces Signed Joint Venture Agreement with Dakota Life Sciences
January 3, 2017

Company provides information regarding a Sublicensing Agreement for Novel Formulations of Bactracin for the Mitigation or Treatment of Highly Drug Resistant Bacterial Infections

Kasten, Inc. (OTC PINK: KAST) is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious conditions arising in the hospital and adjacent clinical settings. Kasten is principally focused on delivering solutions to those clinical wards in which the care pathway is burdened by high morbidity, mortality, and cost.

One particular causative be 64% more likely to die than people with a non-resistant form of the infection. GlobalData forecasts that the MRSA treatment market will grow at a compounded annual growth rate of 3.4% over the next few years to reach $3.5 billion by 2019.

Present antibiotic topical ointments used to prevent or treat Staphylococcus aureus, which often contain bacitracin as an active antimicrobial ingredient, are not effective against hyper-resistant MRSA strains, such as USA300. These strains are in fact highly prevalent in the community and current antibiotic ointments may actually enrich the population of hyper-resistant MRSA. New strategies are needed to control emerging resistant pathogenic bacteria.

Intellectually property has been developed regarding an antimicrobial formulation that significantly potentiates the activity of bacitracin by using alkyl gallates, a group of antioxidants that are currently utilized as food preservatives. The combination of agent of high morbidity and mortality in the hospital setting is drug resistant Staphylococcus aureus. In particular, methicillin-resistant S. aureus (MRSA) is responsible for, according to the CDC, over 80,000 invasive infections and 11,285 related deaths occur every year in the U.S. alone. In fact, people with MRSA are estimated to bacitracin with particular alkyl gallates resulted in up to 1,000,000-fold increase in bactericidal activity against hyper-resistant MRSA strain USA300 and other multidrug-resistant human clinical isolates. The intellectual property and data has been sublicensed by Kasten and will be developed for use for the prevention and treatment of drug resistant bacterial infections.

“Kasten is excited to acquire a license to this potential life-saving therapy for MRSA infections,” states Kasten CEO, Jose Delgado. “This transaction demonstrates Kasten’s commitment to acquiring and developing new therapies for the acute care setting that save lives and decrease costs in hospitals.”

Forward-Looking Statements – This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Kasten, Inc. undertakes no obligation to update such statements.

Contact Us